RBC Capital Upgrades Auxilium Pharmaceuticals (AUXL) to Outperform
Tweet
Share
E-mailGet Alerts AUXL Hot Sheet
Price: $36.47 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Join SI Premium – FREE
RBC Capital upgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Sector Perform to Outperform, price target raised from $20 to $26.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $19.73 yesterday.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $19.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Maxim Group Upgrades Co-Diagnostics (CODX) to Buy
- Goldman Sachs Upgrades Lonking Holdings Limited (3339:HK) (LONKF) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
